FDA To Toughen OTC Oversight, Seek New Authority In Wake Of J&J Recalls
This article was originally published in The Tan Sheet
FDA will monitor more closely OTC manufacturing operations and require comprehensive changes at firms with systemic quality deficiencies as a result of its investigation of Johnson & Johnson's McNeil Consumer Healthcare
You may also be interested in...
Quality control problems for Johnson & Johnson's McNeil Consumer Healthcare business and the regulatory and congressional scrutiny that followed dominated the attention of drug and dietary supplement industry stakeholders in 2010.
Johnson & Johnson failed to provide proof that FDA acknowledged the firm's plan for a "phantom" recall of a Motrin product, according to Capitol Hill staff
FDA warns that even though it cannot mandate a drug recall, "it can take more authoritative legal actions" against firms selling defective health products